Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

The primary efficacy end point was HBsAg loss at 24 weeks after the end of treatment. The researchers found that a primary end point event occurred in 7, 3, 12, 23, and 0 percent of patients in ...